Pharmaceutical Medicine

, Volume 25, Issue 2, pp 107–122 | Cite as

Forum

Update
  • 15 Downloads

References

Reference

  1. Behrman RE, Benner JS, Brown JS, et al. Developing the Sentinel System: a national resource for evidence development. New Engl J Med 2011; 364 (6): 498–9PubMedCrossRefGoogle Scholar

Reference

  1. European Medicines Agency. Report on the survey of all paediatric uses of medicinal products in Europe: executive summary. 2011 Jan 6 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2011 Feb 22]Google Scholar

Reference

  1. US Pharmacopeial Convention. Universal standards proposed for prescription container labels to help reduce medication misuse, promote patient understanding [media release]. 2011 Jan 3 [online]. Available from URL: http://www.usp.org [Accessed 2011 Feb 22]Google Scholar

Reference

  1. O’Dowd A. Scrutiny phase brings chance of change to NHS reform bill. BMJ 2011; 342: d837CrossRefGoogle Scholar

Reference

  1. Stafford N. Switzerland is to fund complementary therapies for six years while effectiveness is evaluated. BMJ 2011; 342: d819PubMedCrossRefGoogle Scholar

Reference

  1. Watson R. European parliament agrees rules on cross border healthcare. BMJ 2011; 342: d492PubMedCrossRefGoogle Scholar

Reference

  1. Bloomberg. Kangmei, China drug makers’ shares tumble on report of further price cuts. 2010 Dec 20 [online]. Available from URL: http://www.bloomberg.com [Accessed 2010 Dec 22]Google Scholar

References

  1. 1.
    Parfitt T. Russia’s drug-supply system leaves HIV patients wanting. Lancet 2011; 377 (9763): 369–70PubMedCrossRefGoogle Scholar
  2. 2.
    Osborn A. Russians are unable to buy aspirin, paracetamol, and other basic drugs because of official bungle. BMJ 2011; 342: d579PubMedCrossRefGoogle Scholar

References

  1. Taylor L. Drugmakers sue Czech govt over pricing, insurance moves. 2011 Jan 12 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2011 Jan 13]Google Scholar

Reference

  1. Tufts Center for the Study of Drug Development. U.S. healthcare stakeholders uncertain about benefits of risk evaluation program, according to Tufts Center for the Study of Drug Development [media release]. 2011 Jan 12 [online]. Available from URL: http://csdd.tufts.edu [Accessed 2011 Jan 14]Google Scholar

References

  1. 1.
    Grootendorst P, Hollis A. The Canada-European Union comprehensive economic and trade agreement: an economic impact assessment of proposed pharmaceutical intellectual property provisions. 2011 Feb 7 [online]. Available from URL: http://www.canadiangenerics.ca [Accessed 2011 Feb 10]Google Scholar
  2. 2.
    Canadian Generic Pharmaceutical Association (CGPA). New study: proposals in Canada-EU trade negotiations would add $46 million annually to Newfoundland and Labrador’s prescription drug bill [media release]. 2011 Feb 7 [online]. Available from URL: http://www.canadiangenerics.ca [Accessed 2011 Feb 10]Google Scholar

Reference

  1. BBC News. Free diabetes and blood pressure drugs for Brazilians. 2011 Feb 3 [online]. Available from URL: http://www.bbc.co.uk [Accessed 2011 Feb 10]Google Scholar

Reference

  1. Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 2011; 20 (1): 1–11PubMedCrossRefGoogle Scholar

References

  1. 1.
    NHS Confederation. Remote control: the patient-practitioner relationship in a digital age. 2011 Jan 20 [online]. Available from URL: http://www.nhsconfed.org/Publications/reports/Pages/Remote-control.aspx [Accessed 2011 Jan 21]Google Scholar
  2. 2.
    Cross M. Doctors are reluctant to use telemedicine and misunderstand what patients want, says NHS Confederation report. 2011 Jan 20 [online]. Available from URL: http://www.nhsconfed.org [Accessed 2011 Jan 21]Google Scholar
  3. 3.
    NHS Confederation. A new NHS Confederation report says the over-reliance on treatment delivered through face-to-face contact means the NHS risks being stuck in the technological dark ages as new ways of communication become the norm. 2011 Jan 20 [online]. Available from URL: http://www.nhsconfed.org/OurWork/latestnews/Pages/NHS-risks-falling-behind-on-technology.aspx [Accessed 2011 Jan 21]Google Scholar

Reference

  1. National Institute for Health and Clinical Excellence. Cash boost for psychological therapies to treat mental health. 2011 Feb 2 [online]. Available from URL: http://www.nice.org.uk [Accessed 2011 Feb 4]Google Scholar

Reference

  1. 1.
    Roebuck MC, Liberman JN, Gemmill-Toyama M, et al. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Affairs 2011; 30 (1): 91–9PubMedCrossRefGoogle Scholar
  2. 2.
    Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. Epub 2011 Jan 10Google Scholar
  3. 3.
    Salanitro AH, Kripalani S. Prescription refill management and its effect on adherence. Arch Intern Med. Epub 2011 Jan 10Google Scholar

References

  1. 1.
    Shrank WH, Choudhry NK, Fischer MA, et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med 2010; 153 (10): 633–40PubMedGoogle Scholar
  2. 2.
    Murray MD, Harrison J. Prescription abandonment: another path to medication nonadherence. Ann Intern Med 2010; 153 (10): 680–1PubMedGoogle Scholar

References

  1. 1.
    Society of Actuaries. New Society of Actuaries study estimates $300 billion economic cost due to overweight and obesity [media release]. 2011 Jan 10 [online]. Available from URL: http://www.soa.org [Accessed 2011 Jan 14]Google Scholar
  2. 2.
    Behan DF, Cox SH, Lin Y, et al. Obesity and its relation to mortality and morbidity costs. 2010 Dec [online]. Available from URL: http://www.soa.org [Accessed 2011 Jan 14]Google Scholar

Reference

  1. Hoggatt J. Personalized medicine: trends in molecular diagnostics: exponential growth expected in the next ten years. 2011 Feb 9 [online]. Available from URL: http://www.in-thought.com [Accessed 2011 Feb 11]Google Scholar

Reference

  1. Seruga B, Sterling L, Wang L, et al. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011; 29 (2): 174–85PubMedCrossRefGoogle Scholar

Reference

  1. Lakdawalla D, Penrod J, Maclean R, et al. Measuring the cost-effectiveness (CE) of therapies treating metastatic colorectal cancer (mCRC) [abstract no. 405]. 2011 Gastrointestinal Cancers Symposium; 2011 Jan 20–22; San Francisco, CA [online]. Available from URL: http://www.asco.org [Accessed 2011 Mar 4]Google Scholar

References

  1. 1.
    Blind E, Dunder K, de Graeff PA, et al. Rosiglitazone: a European regulatory perspective. Diabetologia 2011; 54 (2): 213–8PubMedCrossRefGoogle Scholar
  2. 2.
    European Association for the Study of Diabetes. The leading European agencies for medical products inform the academic public regarding the decision process which resulted in the recommendation to withdraw rosiglitazone from the European market [media release]. 2010 Dec 14 [online]. Available from URL: http://www.easd.org [Accessed 2011 Feb 28]Google Scholar

Reference

  1. Keyhani S, Kim A, Mann M, et al. A new independent authority is needed to issue National Health Care guidelines. Health Affairs 2011; 30 (2): 256–65PubMedCrossRefGoogle Scholar

References

  1. 1.
    Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011; 20 (2): 177–84PubMedCrossRefGoogle Scholar
  2. 2.
    Stanford University School of Medicine. Evidence lacking for widespread use of costly antipsychotic drugs, says researcher [media release]. 2011 Jan 7 [online]. Available from URL: http://med.stanford.edu [Accessed 2011 Feb 28]Google Scholar

References

  1. 1.
    Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol 2011; 12 (1): 65–82PubMedCrossRefGoogle Scholar
  2. 2.
    Lindholm LH, Carlberg B. Blood-pressure drugs and cancer: much ado about nothing? Lancet Oncol 2011; 12 (1): 6–8PubMedCrossRefGoogle Scholar

Reference

  1. Medicines and Healthcare products Regulatory Agency. Seasonal flu vaccines: no evidence of an increased risk of febrile convulsions in children. 2010 Dec 23 [online]. Available from URL: http://www.mhra.gov.uk [Accessed 2011 Jan 20]Google Scholar

Reference

  1. Orriols L, Delorme B, Gadegbeku B, et al. Prescription medicines and the risk of road traffic crashes: a French registry-based study. PLoS Medicine 2010; 7 (11): 1–10CrossRefGoogle Scholar

References

  1. 1.
    Amir E, Ocaña A, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients [abstract no. S2–7]. 33rd Annual SanAntonio Breast Cancer Symposium; 2010 Dec 8–12; San Antonio, TX [online]. Available from URL: http://www.sabcs.org [Accessed 2011 Jan 20]Google Scholar
  2. 2.
    WebMD. Aromatase inhibitors may raise heart risks [media release]. 2010 Dec 9 [online]. Available from URL: http://www.webmd.com [Accessed 2011 Jan 20]Google Scholar

Reference

  1. Jetter G, Moreno L, Rogers S, et al. Cross-section study of 389 veterans analyzing the effect of AEDs on cholesterol levels and simvastatin dose utilization in clinical practice [abstract no. 2.150]. 64th Annual Meeting of the American Epilepsy Society; 2010 Dec 3–7; San Antonio, TX [online]. Available from URL: http://www.aesnet.org [Accessed 2011 Mar 9]Google Scholar

Reference

  1. Lipshultz SE, Shearer WT, Thompson B, et al. Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers. J Am Coll Cardiol 2011 57 (1): 76–85PubMedCrossRefGoogle Scholar

References

  1. 1.
    Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med 2010; 170 (22): 1968–78PubMedCrossRefGoogle Scholar
  2. 2.
    Solomon DH, Rassen JA, Glynn RJ, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010; 170 (22): 1979–86PubMedCrossRefGoogle Scholar

References

  1. 1.
    Westover MB, Bianchi MT, Eckman MH, et al. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol. Epub 2011 Jan 10Google Scholar
  2. 2.
    Goldstein LB. Statins after intracerebral hemorrhage: to treat or not to treat. Arch Neurol. Epub 2011 Jan 10Google Scholar
  3. 3.
    Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. 2011 Jan [online]. Available from URL: http://www.thecochranelibrary.com [Accessed 2011 Jan 21]Google Scholar
  4. 4.
    Dennis M. Review: statins should be used with caution in patients at low risk of cardiovascular disease. 2011 Jan 19 [online]. Available from URL: http://www.firstwordplus.com [Accessed 2011 Jan 21]Google Scholar

Reference

  1. 1.
    Ceschi A, Hofer KE, Rauber-Luthy C, et al. Paracetamol orodispersible tablets: a risk for severe poisoning in children? Eur J Clin Pharmacol 2011; 67 (1): 97–9PubMedCrossRefGoogle Scholar

Reference

  1. Lim A, Cranswick N, South M. Adverse events associated with the use of complementary and alternative medicine in children. Arch Dis Child 2011; 96: 297–300PubMedCrossRefGoogle Scholar

Reference

  1. The National Patient Safety Agency. NPSA calls for safer ambulatory syringe drivers [media release]. 2011 Feb 3 [online]. Available from URL: http://www.npsa.nhs.uk [Accessed 2011 Feb 7]Google Scholar

References

  1. 1.
    European Medicines Agency. Benefit-risk review of Multaq started. 2011 Jan 21 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2011 Jan 28]Google Scholar
  2. 2.
    European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for human use (CHMP): 17–20 January 2011. 2011 Jan 21 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2011 Jan 28]Google Scholar
  3. 3.
    Sanofi Aventis. Information on severe liver injury associated with the use of Multaq (dronedarone). 2011 Jan 19 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2011 Jan 28]Google Scholar

Reference

  1. FDA. FDA drug safety communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. 2011 Jan 12 [online]. Available from URL: http://www.fda.gov [Accessed 2011 Jan 28]Google Scholar

Reference

  1. Biogen Idec, Elan Corporation plc. Biogen Idec and Elan submit applications to update TYSABRI labeling that may help stratify risk of PML with anti-JC virus antibody status [media release]. 2010 Dec 22 [online]. Available from URL: http://www.elan.com [Accessed 2011 Jan 12]Google Scholar

References

  1. 1.
    Stephens C, Borraz Y, Lucena MI, et al. Second DILI episode in patients with previous hepatotoxicity related to a different drug. Analysis of the cases included in the Spanish DILI Registry [abstract no. 269]. 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010Oct 29–Nov 2; Boston (MA) [online]. Available from URL: http://www.aasld.org [Accessed 2011 Jan 28]Google Scholar
  2. 2.
    Borraz Y, Fernandez MC, Garcia-Muhoz B, et al. Would it be desirable to modify the cut-off point for definition of chronicity in drug-induced liver injury (DILI)? [abstract no. 270]. 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010 Oct 29–Nov 2; Boston (MA) [online]. Available from URL: http://www.aasld.org [Accessed 2011 Jan 28]Google Scholar
  3. 3.
    Mishra P, Gelperin K, Lee J, et al. Drug-induced liver injury (Dili) associated with leflunomide use in rheumatoid arthritis patients: case severity and causality adjudication using the DILIN (Drug-Induced Liver Injury Network) criteria [abstract no. 271]. 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010 Oct 29–Nov 2; Boston (MA) [online]. Available from URL: http://www.aasld.org [Accessed 2011 Jan 28]Google Scholar

Copyright information

© Adis Data Information BV 2011

Personalised recommendations